Postmenopausal hormones and coronary heart disease

Current Opinion in Cardiology

Volumn 11, Issue 4, 1996, Pages 440-446

  Rich Edwards, Janet W ^a   Hennekens, Charles H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ALZHEIMER DISEASE; BREAST CANCER; CAUSE OF DEATH; CLINICAL TRIAL; COLON CANCER; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MEDICAL INFORMATION; OSTEOPOROSIS; POSTMENOPAUSE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STROKE;

AGED; BREAST NEOPLASMS; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS;

EID: 0029953416     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199607000-00014     Document Type: Review

References (68)

1. Grady D, Rubin S, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016-1037. Quantitative review of the risks and benefits of HRT on endometrial cancer, breast cancer, CHD, osteoporosis, and stroke. Pooled relative risks for hormone use and lifetable estimates of life expectancy with or without hormone use are provided. Estimates are provided for combination therapy as well as unopposed estrogen therapy.
2. Goldman L, Tosteson ANA: Uncertainty about postmenopausal estrogen: time for action, not debate. N Engl J Med 1991, 325:800-802.
3. Gorsky RD, Koplan JP, Peterson HB, Thacker SB: Relative risks and benefits of long-term estrogen replacement therapy: a decision analysis. Obstet Gynecol 1994, 83:161-166. A decision analysis of the value of ERT for postmenopausal women that accounts for the risk of disease as well as quality of life.
4. National Center for Health Statistics: Vital Statistics of the United States, 1989, Vol II. Mortality, Part A. Washington, DC: Government Printing Office; 1993. [DHHS publication no. (PHS) 93-1101.]
5. Stampfer MJ, Colditz GA, Willett WC: Menopause and heart disease: a review. Ann N Y Acad Sci 1990, 592:193-203.
6. Bush TL: Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In The menopause: Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Edited by Korenman SG, Norwell, MA: Soreno Symposia; 1990:211-223.
7. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD: Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995, 85:1128-1132. Report of a prospective cohort study among 40,000 postmenopausal women followed up for 6 years as part of the Iowa Women's Health Study. Relative risks of total mortality, CHD mortality, and cancer and hip fracture incidence are provided for HRT users compared with nonusers.
8. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koespell TD, Wahl PW, Siscovick DS, Wagner EG: The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994, 154:1333-1339.
9. Ettinger B, Friedman GD, Bush R, Quesenberry CP Jr: Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996, 87:1-7. Report of a large study linking medical records with pharmacy records of HRT use among postmenopausal Kaiser-Permanente patients. Compares total and cause-specific mortality among elderly long-term users of ERT to that among nonusers.
10. Sullivan JM, Zwagg RV, Lemp GF, et al.: Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988, 108:358-363.
11. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA: Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988, 115:954-963.
12. McFarland KF, Boniface ME, Hornung CA, Earnhardt W, Humphries JO: Risk factors and noncontraceptive estrogen use in women with and without coronary disease. Am Heart J 1989, 117:1209-1214.
13. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE: Effects of estrogen replacement on serum lipid valves and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol 1992, 69:176-178.
14. Bush TL, Miller VT: Effects of pharmacologic agents used during menopause: impact on lipids and lipoproteins. In Menopause: Physiology and Pharmacology. Edited by Mishell D. Chicago: Year Book Medical Publishers; 1986;187-208.
15. Miller VT, Muesing RA, LaRosa JC, Stoy DB, Phillips EA, Stillman RJ: Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-1. Obstet Gynecol 1991, 77:235-240.
16. Lindheim SR, Notelovitz M, Feldman EB, Larsen S, Khan FY, Lobo RA: The independent effects of exercise and estrogen on lipids and lipoproteins in postmenopausal women. Obstet Gynecol 1994, 83:167-172.
17. Sack MN, Rader DJ, Cannon RO: Oestrogen and inhibition of oxidation of low density lipoproteins in postmenopausal women. Lancet 1994, 343:269-270.
18. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss F, Wu KK, Szklo M, for the Atherosclerosis Risk in Communities Study Investigators: Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993, 328:1069-1075.
19. Mendoza S, Velazquez E, Osona A, Hamer T, Glueck CJ: Postmenopausal cyclic estrogen/progestin therapy lowers lipoprotein (a). J Lab Clin Med 1994, 123:837-841.
20. Gangar KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S: Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet 1991, 338:839-842.
21. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO: Acute vascular effects of estrogen in postmenopausal women. Circulation 1994, 90:786-791.
22. Leiberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Fanz P, Yeung AC, Creager MA: Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994, 121:936-941.
23. Ylikorkala O, Kuusi T, Tikkanen MJ, Viinikka L: Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. J Clin Endocrinol Metab 1987, 65:1238-1242.
24. Gebara OCE, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PWF, Levy D, Muller JE, Tofler GH: Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995, 91:1952-1958.
25. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995, 273:199-208. Report of a 3-year randomized, double-blind, placebo-controlled trial among 875 healthy postmenopausal women testing the effect of unopposed estrogen and each of three estrogen/progestin regimens on heart disease risk factors.
26. Barrett-Connor E, Laakso M: Ischemic heart disease risk in postmenopausal women; effects of estrogen use on glucose and insulin levels. Arteriosclerosis 1990, 10:531-553.
27. Manson JE, Rimm EB, Colditz GA, Willett WC, Nathan DM, Arky RA, Rosner B, Hennekens CH, Speizer FE, Stampfer MJ: A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol 1992, 2:665-673.
28. Haarbo J, Marslew U, Gotfredsen A, Christiansen C: Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 1991, 40:1323-1326.
29. Lobo RA: Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991, 73:925-930.
30. Castelli WP: Cardiovascular disease in women. Am J Obstet Gynecol 1988, 158:1553-1560.
31. Hunt K, Vessey M, McPherson K: Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990, 978:1080-1086.
32. Falkeborn M, Persson I, Adami HO, Bergstrom R, Eaker E, Lithall H, Mohsen R, Naessen T: The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992, 99:821-828.
33. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM: Estrogen replacement therapy: II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979, 54:74-79.
34. Thompson SG, Meade TW, Green G: The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Commun Health 1989, 43:173-178.
35. Finucane RR, Madans JH, Bush TL, Wolf PH, Kleinman JC: Decreased risk of stroke among postmenopausal hormone users: results from a national cohort. Arch Intern Med 1993, 153:73-79.
36. Folsom AR, Mink PJ, Sellers TA, Hong C-P, Zheng W, Potter JD: Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995, 85:1128-1132.
37. Steinberg KK, Thacker SB, Smith SJ, et al.: A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991, 265:1985-1990.
38. Colditz GA, Egan KM, Stampfer MJ: Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 1993, 168:1473-1480.
39. Dupont WD, Page DL: Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991, 151:67-72.
40. Sillero-Arenas M, Delgado-Rodriguez M, Rodriguez-Contreras R, Bueno-Cavanillas A, Galvez-Vargas R: Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1993, 168:1473-1480.
41. Brinton L, Schairer C: Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993, 15:66-79.
42. Going JJ, Anderson TJ, Battersby S, Macintyre CCA: Proliferate and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988, 130:193-204.
43. Potten CS, Watson RJ, Williams GT, et al.: The effect of age and menstrual cycle upon proliferate activity of normal human breast. Br J Cancer 1988, 58:163-170.
44. Anderson RJ, Battersby S, King RJB, McPherson K, Going JJ: Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989, 20:1139-1144.
45. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995, 332:1589-1593.
46. Colditz GA, Willett WC, Sepzier FE: Breast cancer and hormone-replacement therapy. N Engl J Med 1995, 333:1357-1358.
47. Schuurman AG, van den Brandt PA, Goldbohm RA: Exogenous hormone use and the risk of postmenopausal breast cancer: results from the Netherlands Cohort Study. Cancer Causes Control 1995, 6:416-424.
48. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995, 274:137-142.
49. Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, Bogdan G, Willett WC: Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995, 142:788-795.
50. Schairer C, Byren C, Keyl PM, Brinton LA, Sturgeon Sr, Hoover RN: Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994, 5:491-500.
51. Nguyen TV, Jones F, Sambrook PH, White CP, Kelly PJ, Eisman JA: Effects of estrogen exposure and reproductive factors on bone mineral density and osteoporotic fractures. J Clin Endocrinol Metab 1995, 80:2709-2714.
52. Marcus R, Greendale G, Blunt BA, et al.: Correlates of bone density in the postmenopausal estrogen/progestin interventions trial. J Bone Miner Res 1994, 9:1467-1476.
53. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ: The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993, 329:1141-1146.
54. Ettinger B, Grady D: The waning effect of postmenopausal estrogen therapy on osteoporosis. N Engl J Med 1993, 329:1192-1193.
55. McMichael AJ, Potter JD: Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst 1980, 65:1201-1207.
56. Francavilla A, Di Leo A, Polimeno L, et al.: Nuclear and cytosolic estrogen receptors in human colon carcinoma and in surrounding noncancerous colonic tissue. Gastroenterology 1987, 93:1301-1306.
57. Pertsemlidis D, Panveliwalla DM, Ahrens EH Jr: Effects of clofibrate and of an estrogen-progestin combination of fasting biliary lipids and cholic acid kinetics in man. Gastroenterology 1974, 66:565-573.
58. Calle EE, Miracle-McMahil HL, Thun MJ, Heath CW Jr: Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995, 87:517-523.
59. Rocca WA, Hofman A, Brayne C, et al.: Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. Ann Neurol 1991, 30:381-390.
60. Luine VN: estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985, 89:484-490.
61. Toran-Allerand CD, Miranda RC, Bentham WDL, et al.: Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992, 89:4668-4672.
62. Fillit HM, Ashly D, Cholst I, et al.: Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986, 11:337-345.
63. Honjo H, Ogino Y, Naitoh K, et al.: In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 1989, 34:511-515.
64. Paganini-Hill A, Henderson VW: estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994, 140:256-261.
65. Barrett-Connor E, Kritz-Silverstein D: Estrogen replacement therapy and cognitive function in older women. JAMA 1993, 269:2637-2641.
66. Brenner DE, Kukull WA, Stergachis A, van Belle G, Bowen JD, McCormick WC, Teri L, Larson EB: Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol 194, 140:262-267.
67. Barrett-Connor E: Postmenopausal estrogen and prevention bias. Ann Intern Med 1991, 115:455-465.
68. Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991, 20:47-63.